Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-COP in AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
NCT00389818Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Jan 2007
- Primary completion
- Sep 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in B-cell non-Hodgkin lymphoma, sponsored by AIDS Malignancy Consortium. Primary endpoints: Complete Response Rate (Complete Response and Complete Response Unconfirmed), Duration of Response (Relapse-free survival) up to 3 years and 2 more. Started Jan 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00389818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389818.